Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Encephalitis autoimmune
ADR ID BADD_A09163
ADR Hierarchy
10      Immune system disorders
10.04      Autoimmune disorders
10.04.10      Nervous system autoimmune disorders
10.04.10.012      Encephalitis autoimmune
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.32      Neoplasm related morbidities
16.32.01      Paraneoplastic syndromes NEC
16.32.01.006      Encephalitis autoimmune
17      Nervous system disorders
17.06      Central nervous system infections and inflammations
17.06.05      Encephalitis NEC
17.06.05.002      Encephalitis autoimmune
Description Disorder characterized by symptoms of CATATONIA; HYPOVENTILATION; DYSKINESIAS; ENCEPHALITIS; and SEIZURES followed by a reduced CONSCIOUSNESS. It is often followed by a viral-like prodrome. Many cases are self-limiting and respond well to IMMUNOMODULATORY THERAPIES against the NMDA RECEPTORS antibodies. [MeSH]
MedDRA Code 10072378
MeSH ID D060426; D020363
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Encephalitis autoimmune | Anti-NMDA receptor encephalitis | Limbic encephalitis | Paraneoplastic limbic encephalitis | NMDA-R encephalitis | LGI1 antibody encephalitis | VGKC antibody encephalitis | CASPR2-antibody encephalitis | Anti-N-Methyl-D-Aspartate Receptor Encephalitis | Anti N Methyl D Aspartate Receptor Encephalitis | Anti-N-Methyl-D-Aspartate Receptor Encephalitides | Encephalitides, Anti-N-Methyl-D-Aspartate Receptor | Encephalitis, Anti-N-Methyl-D-Aspartate Receptor | Anti-NMDA Receptor Encephalitis | Anti NMDA Receptor Encephalitis | Anti-NMDA Receptor Encephalitides | Encephalitides, Anti-NMDA Receptor | Encephalitis, Anti-NMDA Receptor | Receptor Encephalitides, Anti-NMDA | Receptor Encephalitis, Anti-NMDA | Anti-NMDAR Encephalitis | Anti NMDAR Encephalitis | Anti-NMDAR Encephalitides | Encephalitides, Anti-NMDAR | Encephalitis, Anti-NMDAR | Non-paraneoplastic Anti-N-Methyl-D-Aspartate Receptor Encephalitis | Non paraneoplastic Anti N Methyl D Aspartate Receptor Encephalitis | Non-paraneoplastic Anti-NMDAR Encephalitis | Anti-NMDAR Encephalitides, Non-paraneoplastic | Anti-NMDAR Encephalitis, Non-paraneoplastic | Encephalitides, Non-paraneoplastic Anti-NMDAR | Encephalitis, Non-paraneoplastic Anti-NMDAR | Non paraneoplastic Anti NMDAR Encephalitis | Non-paraneoplastic Anti-NMDAR Encephalitides | Non-paraneoplastic Anti-NMDA Receptor Encephalitis | Non paraneoplastic Anti NMDA Receptor Encephalitis | Paraneoplastic Anti-N-Methyl-D-Aspartate Receptor Encephalitis | Paraneoplastic Anti N Methyl D Aspartate Receptor Encephalitis | Paraneoplastic Anti-NMDAR Encephalitis | Anti-NMDAR Encephalitides, Paraneoplastic | Anti-NMDAR Encephalitis, Paraneoplastic | Encephalitides, Paraneoplastic Anti-NMDAR | Encephalitis, Paraneoplastic Anti-NMDAR | Paraneoplastic Anti NMDAR Encephalitis | Paraneoplastic Anti-NMDAR Encephalitides | Paraneoplastic Anti-NMDA Receptor Encephalitis | Paraneoplastic Anti NMDA Receptor Encephalitis
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00165Aripiprazole0.000079%
BADD_D00356Carbamazepine0.000186%
BADD_D00511Clozapine0.001834%
BADD_D01238Lacosamide0.001463%
BADD_D01243Lamotrigine0.000083%
BADD_D01265Levetiracetam0.000755%
BADD_D01599Olanzapine0.000316%
BADD_D01629Osimertinib0.000112%
BADD_D01633Oxaliplatin0.000112%
BADD_D01831Prednisolone0.000035%
BADD_D01951Risperidone0.000242%
BADD_D02105Tacrolimus0.001040%
BADD_D02329Valproic acid0.000150%
BADD_D02464Fingolimod0.000482%
BADD_D02511Siponimod0.000241%
The 1th Page    1    Total 1 Pages